Biotech entity
All 1 tracked stories fall under one category: pharma. 300U Tubeless Patch Pump is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention DDG 2026, all published on July 27, 2026.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. 300U Tubeless Patch Pump is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention DDG 2026, all published on July 27, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering DDG 2026. Shared-story counts are live from our verified record — not editorial picks.
Medtrum is advancing its 300U tubeless insulin pump toward the German market, leveraging its in-house APGO automated insulin delivery algorithm. The device’s reimbursement listing in Germany could pressure competitors like Insulet and Medtronic in the automated diabetes management space. Biopharma investors should watch for clinical evidence and partnership developments.
Source: manilatimes.net · prnewswire.com
DDG 2026 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
